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Clinical presentations of hemophagocytic lymphohistiocy-
tosis (HLH) and septic shock share many similarities, in-
cluding multiple organ dysfunction and overall clinical
and biological symptoms. However, these life-threatening
conditions require specific and opposing treatments. Cur-
rently, no single biomarker is available to differentiate sep-
tic shock from HLH at patient admission [1, 2]. HLH is
classified as a primary (genetically inherited) or a second-
ary, i.e., induced by various inflammatory conditions (viral
infections, autoimmune processes, lymphoid malignan-
cies, or drug allergies), immune disorder. We report here
the case of a young woman with febrile shock which
proved to be a HLH caused by drug-induced hypersensi-
tivity syndrome (DIHS). As septic shock was initially sus-
pected, the patient benefited from broad immunological
screening during the first week of evolution [3]. Strikingly,
this revealed massively increased expression of monocyte
human leukocyte antigen-DR (mHLA-DR) at 137,021
ABC (antibody bound per cell), even though expected
values in septic shock are usually drastically decreased [3].
In addition, a positive response to increasing doses of cor-
ticosteroids was observed over time (Fig. 1). More pre-
cisely, while the patient’s mHLA-DR expression was
measured at 137,021 ABC at admission, it decreased to
38,961 ABC after the introduction of corticosteroids (day
3). Following the reactivation of inflammatory processes
(day 5), mHLA-DR rose again (66,829 ABC). Finally,
mHLA-DR returned to a normal range after increasing
corticosteroid doses (20,499 ABC, day 8). All clinical fea-
tures are provided in Additional file 1.
In the present patient, the extremely increased in-
augural mHLA-DR value (i.e., 137,021 ABC) helped
to unequivocally exclude a diagnosis of septic shock.
Indeed, in our experience (more than 600 septic
shock patients monitored over several years), the vast
majority of mHLA-DR values measured within the
first 3 days after septic shock are reported to be
< 30,000 ABC and mostly found below 10,000 ABC
(normal values ranged from 15,000 to 40,000 ABC).
This agrees with pathophysiology since HLH is
secondary to overproduction of interferon-γ (IFN-γ),
a cytokine known to be a strong inducer of
mHLA-DR expression, whereas sepsis induces down-
regulation of mHLA-DR expression.
In conclusion, mHLA-DR may discriminate septic
shock from HLH at admission despite both situations
with multiple organ dysfunction sharing very common
clinical and biological features (e.g., sCD25, elevated
ferritin levels) [4, 5]. This result obviously needs fur-
ther assessment in various types of HLH. Upon con-
firmation, as these two deadly conditions (i.e., septic
shock and HLH) would require opposing treatments,
mHLA-DR may be of crucial help for clinicians re-
garding patients’ care and management.
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Fig. 1 Time course of mHLA-DR in a HLH patient. Blue squares
depict mHLA-DR values in the HLH patient. Red circles represent
pediatric septic shock values [3]. Gray range represents interquartile
range values obtained previously in healthy children [3].
*Corticosteroids introduced, receiving 2 mg/kg/day; **corticosteroid
adjustment to 4 mg/kg/day
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